Time to end secret data laboratories—starting with the CDC
The American people are waking up to the fact that too many public health leaders have not always been straight with them. Despite housing treasure…
Thought Leader: Marty Makary
Dr. Scott Gottlieb on HHS Secretary RFK Jr.’s newly appointed vaccine advisory panel
Dr. Scott Gottlieb served as FDA commissioner in President Trump’s first term, and is currently on the board at Pfizer and the chairman of the board at Illumina. He tells “Face the Nation with Margaret Brennan” that “this does look like a political process right now” as Health and Human Services Secretary Robert F. Kennedy has made changes to the vaccine advisory panel ACIP.
Dr. Scott Gottlieb, former Commissioner of the U.S. Food and Drug Administration, is one of today’s most trusted voices in healthcare policy and pharmaceutical innovation. With deep experience at the highest levels of public health leadership, Dr. Gottlieb offers expert analysis on the evolving landscape of healthcare regulation, drug development, biopharma trends, and global market forces such as tariffs and supply chain disruption. A physician, policymaker, and thought leader, he regularly advises organizations navigating complex health and economic challenges. His insights are essential for anyone seeking clarity at the intersection of science, policy, and innovation. For speaking inquiries, contact WWSG.
Relevant posts
Newt Gingrich | Election 2024 – State of the Race
Newt Gingrich discusses the upcoming election with two experienced pollsters, John McLaughlin and Doug Sosnik. They discuss key issues voters are considering, the six or…
Jay Clayton on taxing unrealized gains, price gouging ban proposals
Former SEC Chair Jay Clayton joins ‘Squawk Box’ to discuss the Trump vs. Harris economic agendas, taxing unrealized capital gains, federal price gouging ban, and…
More with this speaker
Scott Gottlieb Joins Face the Nation
Thought Leader: Scott Gottlieb
Scott Gottlieb on CAR-T, Lilly Deal, Psychedelics
Thought Leader: Scott Gottlieb
Scott Gottlieb on FDA’s New Rare Disease Framework
Thought Leader: Scott Gottlieb